Targeting the programmed cell death-1 pathway in breast and ovarian cancer

Leisha A. Emens, Marleen Kok, Laureen S. Ojalvo

Research output: Contribution to journalArticle

Abstract

Purpose of review: Immune checkpoint blockade is changing cancer therapy. Targeting the programmed cell death-1 (PD-1) pathway releases T cells from inhibitory signals within the tumor microenvironment, thereby activating a latent antitumor immune response. Here, we review the biology underlying the activity of PD-1/programmed cell death-ligand 1 (PD-L1) antagonists, and data describing their clinical activity in breast and ovarian cancer. Recent findings: Several antagonists of PD-1 and PD-L1 have been tested in breast and ovarian cancer. These drugs are generally well tolerated, with some immune-related adverse events that are typically easily managed. Objective response rates generally range from about 10 to 20% in both breast cancer and ovarian cancer, with durable responses noted in multiple trials. Selecting patients with PD-L1 expression by cells within the tumor microenvironment appears to enrich for responses. These agents are under accelerated development based on these promising early data. Summary: Monoclonal antibody-based blockade of the PD-1 pathway results in objective and durable clinical responses in a subset of patients with breast or ovarian cancers, particularly those with PD-L1-positive cells within the tumor microenvironment. Current priorities are to refine biomarkers of therapeutic response, and to develop combination immunotherapy strategies that integrate PD-1/PD-L1 antagonists with both standard and immune-based cancer therapies to increase efficacy.

Original languageEnglish (US)
Pages (from-to)142-147
Number of pages6
JournalCurrent Opinion in Obstetrics and Gynecology
Volume28
Issue number2
DOIs
StatePublished - Apr 1 2016

Fingerprint

Ovarian Neoplasms
CD274 Antigen
Cell Death
Breast Neoplasms
Tumor Microenvironment
Ligands
Immunotherapy
Neoplasms
Therapeutics
Biomarkers
Monoclonal Antibodies
T-Lymphocytes
Pharmaceutical Preparations

Keywords

  • breast cancer
  • immune checkpoint blockade
  • immunotherapy
  • ovarian cancer

ASJC Scopus subject areas

  • Obstetrics and Gynecology

Cite this

Targeting the programmed cell death-1 pathway in breast and ovarian cancer. / Emens, Leisha A.; Kok, Marleen; Ojalvo, Laureen S.

In: Current Opinion in Obstetrics and Gynecology, Vol. 28, No. 2, 01.04.2016, p. 142-147.

Research output: Contribution to journalArticle

Emens, Leisha A. ; Kok, Marleen ; Ojalvo, Laureen S. / Targeting the programmed cell death-1 pathway in breast and ovarian cancer. In: Current Opinion in Obstetrics and Gynecology. 2016 ; Vol. 28, No. 2. pp. 142-147.
@article{894811a64d134182853616a49e7663c7,
title = "Targeting the programmed cell death-1 pathway in breast and ovarian cancer",
abstract = "Purpose of review: Immune checkpoint blockade is changing cancer therapy. Targeting the programmed cell death-1 (PD-1) pathway releases T cells from inhibitory signals within the tumor microenvironment, thereby activating a latent antitumor immune response. Here, we review the biology underlying the activity of PD-1/programmed cell death-ligand 1 (PD-L1) antagonists, and data describing their clinical activity in breast and ovarian cancer. Recent findings: Several antagonists of PD-1 and PD-L1 have been tested in breast and ovarian cancer. These drugs are generally well tolerated, with some immune-related adverse events that are typically easily managed. Objective response rates generally range from about 10 to 20{\%} in both breast cancer and ovarian cancer, with durable responses noted in multiple trials. Selecting patients with PD-L1 expression by cells within the tumor microenvironment appears to enrich for responses. These agents are under accelerated development based on these promising early data. Summary: Monoclonal antibody-based blockade of the PD-1 pathway results in objective and durable clinical responses in a subset of patients with breast or ovarian cancers, particularly those with PD-L1-positive cells within the tumor microenvironment. Current priorities are to refine biomarkers of therapeutic response, and to develop combination immunotherapy strategies that integrate PD-1/PD-L1 antagonists with both standard and immune-based cancer therapies to increase efficacy.",
keywords = "breast cancer, immune checkpoint blockade, immunotherapy, ovarian cancer",
author = "Emens, {Leisha A.} and Marleen Kok and Ojalvo, {Laureen S.}",
year = "2016",
month = "4",
day = "1",
doi = "10.1097/GCO.0000000000000257",
language = "English (US)",
volume = "28",
pages = "142--147",
journal = "Current Opinion in Obstetrics and Gynecology",
issn = "1040-872X",
publisher = "Lippincott Williams and Wilkins",
number = "2",

}

TY - JOUR

T1 - Targeting the programmed cell death-1 pathway in breast and ovarian cancer

AU - Emens, Leisha A.

AU - Kok, Marleen

AU - Ojalvo, Laureen S.

PY - 2016/4/1

Y1 - 2016/4/1

N2 - Purpose of review: Immune checkpoint blockade is changing cancer therapy. Targeting the programmed cell death-1 (PD-1) pathway releases T cells from inhibitory signals within the tumor microenvironment, thereby activating a latent antitumor immune response. Here, we review the biology underlying the activity of PD-1/programmed cell death-ligand 1 (PD-L1) antagonists, and data describing their clinical activity in breast and ovarian cancer. Recent findings: Several antagonists of PD-1 and PD-L1 have been tested in breast and ovarian cancer. These drugs are generally well tolerated, with some immune-related adverse events that are typically easily managed. Objective response rates generally range from about 10 to 20% in both breast cancer and ovarian cancer, with durable responses noted in multiple trials. Selecting patients with PD-L1 expression by cells within the tumor microenvironment appears to enrich for responses. These agents are under accelerated development based on these promising early data. Summary: Monoclonal antibody-based blockade of the PD-1 pathway results in objective and durable clinical responses in a subset of patients with breast or ovarian cancers, particularly those with PD-L1-positive cells within the tumor microenvironment. Current priorities are to refine biomarkers of therapeutic response, and to develop combination immunotherapy strategies that integrate PD-1/PD-L1 antagonists with both standard and immune-based cancer therapies to increase efficacy.

AB - Purpose of review: Immune checkpoint blockade is changing cancer therapy. Targeting the programmed cell death-1 (PD-1) pathway releases T cells from inhibitory signals within the tumor microenvironment, thereby activating a latent antitumor immune response. Here, we review the biology underlying the activity of PD-1/programmed cell death-ligand 1 (PD-L1) antagonists, and data describing their clinical activity in breast and ovarian cancer. Recent findings: Several antagonists of PD-1 and PD-L1 have been tested in breast and ovarian cancer. These drugs are generally well tolerated, with some immune-related adverse events that are typically easily managed. Objective response rates generally range from about 10 to 20% in both breast cancer and ovarian cancer, with durable responses noted in multiple trials. Selecting patients with PD-L1 expression by cells within the tumor microenvironment appears to enrich for responses. These agents are under accelerated development based on these promising early data. Summary: Monoclonal antibody-based blockade of the PD-1 pathway results in objective and durable clinical responses in a subset of patients with breast or ovarian cancers, particularly those with PD-L1-positive cells within the tumor microenvironment. Current priorities are to refine biomarkers of therapeutic response, and to develop combination immunotherapy strategies that integrate PD-1/PD-L1 antagonists with both standard and immune-based cancer therapies to increase efficacy.

KW - breast cancer

KW - immune checkpoint blockade

KW - immunotherapy

KW - ovarian cancer

UR - http://www.scopus.com/inward/record.url?scp=84960385383&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84960385383&partnerID=8YFLogxK

U2 - 10.1097/GCO.0000000000000257

DO - 10.1097/GCO.0000000000000257

M3 - Article

VL - 28

SP - 142

EP - 147

JO - Current Opinion in Obstetrics and Gynecology

JF - Current Opinion in Obstetrics and Gynecology

SN - 1040-872X

IS - 2

ER -